Initial Therapy
(n=23)
|
WLE & SLNB
WLE
Immunotherapy
|
18 (78.3)
5 (21.7)
8 (34.8)
|
2 (100)
|
1 (50)
1 (50)
|
3 (50)
3 (50)
|
4 (100)
|
9 (100)
8 (88.9)
|
Response
(n=23)
|
No progression/recurrence
Progression
Recurrence
|
21 (91.3)
2 (8.7)
|
|
2 (100)
1 (50)
|
6 (100)
|
4 (100)
|
8 (88.9)
1 (11.1)
|
Margins (n=23)
|
Positive
Negative
|
9 (39.1)
14 (56.5)
|
2 (100)
|
1 (50)
1 (50)
|
2 (33.3)
4 (66.7)
|
2 (50)
2 (50)
|
4 (44.4)
5 (55.6)
|
Ulceration
(n=21)
|
Yes
No
|
3 (13)
18 (78)
|
1 (50)
|
2 (100)
|
6 (100)
|
1 (25)
3 (75)
|
2 (22.2)
6 (66.7)
|
Presence of other melanocytic nevi (n=22)
|
Yes
No
|
18 (81.8)
4 (18.2)
|
2 (100)
|
1 (50)
|
4 (66.7)
2 (33.3)
|
4 (100)
|
7 (77.8)
2 (22.2)
|
Therapy at progression or recurrence*
|
Radiation
Surgery
Immunotherapy
|
1 (50)
2 (100)
2 (100)
|
|
|
|
|
1 (50)
2 (100)
2 (100)
|
History of sunburns (n=23)
|
Yes
No
|
6 (26.1)
17 (73.9)
|
1 (50)
1 (50)
|
3 (100)
|
1 (20)
4 (80)
|
2 (50)
2 (50)
|
2 (22.2)
7 (77.8)
|
Family history of melanoma (n=23)
|
Yes
No
|
6 (26.1)
17 (73.9)
|
2 (100)
|
1 (50)
1 (50)
|
2 (33.3)
4 (66.7)
|
1 (25)
3 (75)
|
2 (22.2)
7 (77.8)
|
Family history of dysplastic nevi syndrome (n=23)
|
Yes
No
|
1 (4.3)
22 (95.7)
|
2 (100)
|
2 (100)
|
1 (16.7)
5 (83.3)
|
4 (100)
|
9 (100)
|
Positive SLNB (n = 19)
|
Yes
No
|
11 (47.8)
8 (52.2)
|
2 (100)
|
1 (50)
|
1 (16.7)
2 (40)
|
4 (100)
|
9 (100)
|